ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
-0.04%
Brent Oil
82.765
-1.03%
Bitcoin
63,012.80
6.58%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Takeda Pharmaceutical Co Ltd (0RN3)

  7. Takeda Pharmaceutical Co Ltd (0RN3) News

Takeda Pharmaceutical (0RN3)

Takeda Pharmaceutical Co Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RN3
DateTimeSourceHeadlineSymbolCompany
22/04/202420:41Alliance NewsAlliance NewsTakeda, Astellas and Sumitomo to create new drug discovery companyLSE:0RN3Takeda Pharmaceutical Co Ltd
27/03/202412:56PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAELSE:0RN3Takeda Pharmaceutical Co Ltd
27/03/202412:53PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAELSE:0RN3Takeda Pharmaceutical Co Ltd
09/11/202312:16Alliance NewsAlliance NewsHutchmed hails Takeda's fruquintinib approval from US for cancer formLSE:0RN3Takeda Pharmaceutical Co Ltd
30/10/202312:24Alliance NewsAlliance NewsTakeda Pharmaceutical first half profit falls as costs outpace revenueLSE:0RN3Takeda Pharmaceutical Co Ltd
29/09/202310:12Alliance NewsAlliance NewsHutchmed notes Takeda submits fruquintinib drug application in JapanLSE:0RN3Takeda Pharmaceutical Co Ltd
22/09/202315:15PR Newswire (US)Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and OlderLSE:0RN3Takeda Pharmaceutical Co Ltd
27/07/202310:26Alliance NewsAlliance NewsTakeda keeps guidance unchanged despite drop in quarterly profitLSE:0RN3Takeda Pharmaceutical Co Ltd
12/07/202313:22Alliance NewsAlliance NewsJapan's Takeda pulls dengue vaccine candidate in USLSE:0RN3Takeda Pharmaceutical Co Ltd
12/07/202305:16Alliance NewsAlliance NewsJapan's Takeda pulls dengue vaccine candidate in USLSE:0RN3Takeda Pharmaceutical Co Ltd
16/06/202308:51Alliance NewsAlliance NewsHutchmed, Takeda Fresco-2 study published in The LancetLSE:0RN3Takeda Pharmaceutical Co Ltd
11/05/202311:51Alliance NewsAlliance NewsTOP NEWS: Takeda outlook downbeat as Covid wanes, hit from genericsLSE:0RN3Takeda Pharmaceutical Co Ltd
02/02/202310:57Alliance NewsAlliance NewsTakeda Pharmaceutical set for annual guidance as 9-month results upLSE:0RN3Takeda Pharmaceutical Co Ltd
08/12/202216:49Alliance NewsAlliance NewsTakeda Pharmaceutical gets EC approval for dengue vaccineLSE:0RN3Takeda Pharmaceutical Co Ltd
23/11/202212:49Alliance NewsAlliance NewsIN BRIEF: USD FDA accepts Takeda's TAK-003 for priority reviewLSE:0RN3Takeda Pharmaceutical Co Ltd
28/07/202217:10Alliance NewsAlliance NewsTakeda first quarter profit drops despite revenue increaseLSE:0RN3Takeda Pharmaceutical Co Ltd
11/05/202213:23Alliance NewsAlliance NewsTakeda annual profit drops on investment losses but revenue climbsLSE:0RN3Takeda Pharmaceutical Co Ltd
19/04/202208:19Alliance NewsAlliance NewsTakeda's Nuvaxovid vaccine approved for use in JapanLSE:0RN3Takeda Pharmaceutical Co Ltd
07/09/202106:10Alliance NewsAlliance NewsTakeda inks deal with Japan's government to supply Novavax vaccinesLSE:0RN3Takeda Pharmaceutical Co Ltd
09/06/202117:22PR Newswire (US)Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient communityLSE:0RN3Takeda Pharmaceutical Co Ltd
09/06/202117:21PR Newswire (US)Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient communityLSE:0RN3Takeda Pharmaceutical Co Ltd
11/05/202108:30Alliance NewsAlliance NewsTOP NEWS: Takeda Pharmaceutical profit surges; guides boosted revenueLSE:0RN3Takeda Pharmaceutical Co Ltd
29/10/202007:41Alliance NewsAlliance NewsTOP NEWS: Takeda Pharmaceutical Ups Guidance As Profit Rises In HalfLSE:0RN3Takeda Pharmaceutical Co Ltd
07/08/202011:25Alliance NewsAlliance NewsNovavax Turns To Takeda To Manufacture Covid-19 Vaccine In JapanLSE:0RN3Takeda Pharmaceutical Co Ltd
03/08/202011:35Alliance NewsAlliance NewsGLOBAL TRADING UPDATE SUMMARY: Murata's First-Quarter Profit Drops 15%LSE:0RN3Takeda Pharmaceutical Co Ltd
31/07/202011:04Alliance NewsAlliance NewsTOP NEWS: Takeda Profit More Than Triples In Quarter; Ups GuidanceLSE:0RN3Takeda Pharmaceutical Co Ltd
29/06/202010:06Alliance NewsAlliance NewsTakeda Earnings To Be Hurt By Novartis Pulling Xiidra ApplicationLSE:0RN3Takeda Pharmaceutical Co Ltd
22/06/202010:10Alliance NewsAlliance NewsTakeda Pharmaceutical To Get USD564 Million One-Off Profit BoostLSE:0RN3Takeda Pharmaceutical Co Ltd
15/06/202011:33Alliance NewsAlliance NewsTakeda Pharmaceutical Reports Positive Hemophilia Studies ResultsLSE:0RN3Takeda Pharmaceutical Co Ltd
13/05/202009:15Alliance NewsAlliance NewsTakeda Revenue Rises But Swings To Loss In First Year After Shire BuyLSE:0RN3Takeda Pharmaceutical Co Ltd
 Showing the most relevant articles for your search:LSE:0RN3

Your Recent History

LSE
TERN
Tern
LSE
AGL
Angle
LSE
POS
Plexus
LSE
BIRD
Blackbird
LSE
AAZ
Anglo Asian Mining
LSE
SCE
Surface Transforms
LSE
BT.A
Bt
LSE
PHNX
Phoenix
LSE
AAU
Ariana Resources
LSE
SCLP
Scancell
LSE
GOLD
LSE
IES
Invinity Energy Systems
LSE
VAST
Vast Resources
LSE
ZPHR
Zephyr Energy
LSE
DELT
Deltic Energy
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved